ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 680

Diastolic Dysfunction Amongst Autoantibody Subgroups Of Patients With Diffuse Scleroderma

Cory Perugino1, John Stephens2, Colin O'Rourke3 and Soumya Chatterjee4, 1Internal Medicine, Cleveland Clinic, Cleveland, OH, 2Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies, Cardiovascular disease, scleroderma and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Scleroderma or systemic sclerosis (SSc) is an autoimmune disease characterized by microangiopathy, tissue hypoxia, and fibrosis. At least seven different autoantibodies have been identified with distinct phenotypic associations. A recent study involving patients with limited and diffuse SSc found the prevalence of diastolic dysfunction to be 23%.[1] Serious cardiac involvement defined as symptomatic heart failure, arrhythmia, or pericardial effusion, has been associated with Scl-70 antibodies when compared to RNA polymerase III (Pol-III) positive patients.[2]The aim of this study was to compare prevalence of subclinical diastolic dysfunction in diffuse SSc patients with Pol-III antibodies or Scl-70 antibodies.


[1] Hinchcliff, M; Desai, C; Varga, J; Shah S. Prevalence, Prognosis, and Factors Associated with Left Ventricular Diastolic Dysfunction in Systemic Sclerosis. Clin Exp Rheum. 2012; 30 (2 Suppl 71): S30-S37.

[2] Okano, Y; Steen, V; Medsger, T. Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis. Ann Intern Med. 1993; 119:1005-1013.

Methods:

Forty two patients from a major tertiary referral center with known SSc and Pol-III antibodies provided a cohort of 18 patients after the exclusion of those with limited disease. Similarly, 540 patients diagnosed with SSc were screened for Scl-70 antibodies providing a cohort of 24 patients after the exclusion of those with limited disease phenotype. Demographic and echocardiographic indices for diastology were collected.  Welch’s two-sample t-test and Pearson’s chi-squared test were used for continuous and categorical variables, respectively. Logistic regression was used to compare binary measurements and linear regression models for continuous measurements after adjusting for disease duration. A significance level of 5% was used for all analyses.

Results:

By unadjusted analysis, 26% of the Pol-III patients had diastolic dysfunction, compared to 74% of the Scl-70 group. This difference reached statistical significance with a p-value of 0.035. After adjusting for disease duration, the estimated odds ratio of having diastolic dysfunction was 4.2 times higher for Scl-70 patients than for Pol-III patients. Although the latter finding did not reach statistical significance, it can be thought of as a trend with a p-value of 0.052. There was no evidence that the septal E/E’ ratio, lateral E/E’ ratio, E/A ratio, or left ventricular mass index differ between the two groups.

Conclusion:

Diastolic dysfunction is prevalent amongst SSc patients with diffuse disease. Scl-70 and Pol-III antibodies are associated with diastolic dysfunction in patient with diffuse SSc. After adjusting for disease duration, Scl-70 patients had a proportionally higher prevalence of diastolic dysfunction than Pol-III patients with a trend towards significance. These autoantibodies may be markers of risk for developing myocardial dysfunction.


Disclosure:

C. Perugino,
None;

J. Stephens,
None;

C. O’Rourke,
None;

S. Chatterjee,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diastolic-dysfunction-amongst-autoantibody-subgroups-of-patients-with-diffuse-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology